School of Medicine
Showing 1-10 of 23 Results
-
Jeffrey A. Feinstein, MD, MPH
Dunlevie Family Professor of Pulmonary Vascular Disease and Professor, by courtesy, of Bioengineering
Current Research and Scholarly InterestsResearch interests include (1) computer simulation and modeling of cardiovascular physiology with specific attention paid to congenital heart disease and its treatment, (2) the evaluation and treatment of pulmonary hypertension/pulmonary vascular diseases, and (3) development and testing of medical devices/therapies for the treatment of congenital heart disease and pulmonary vascular diseases.
-
Heidi M. Feldman
Ballinger-Swindells Endowed Professor of Developmental and Behavioral Pediatrics
Current Research and Scholarly InterestsMy current research program focuses on infants born preterm, before 32 weeks gestation from two language environments: English and Spanish. The study considers how neurobiological factors, specifically properties of the white matter circuits in the brain, interact with social, psychological, and economic factors to predict language processing efficiency at 18 months of age.
-
Nielsen Fernandez-Becker
Clinical Associate Professor, Medicine - Gastroenterology & Hepatology
BioI am the director of the Celiac Disease Program at Stanford and I am highly experienced in diagnosis and management of celiac disease and gluten associated disorders.
My objective is to provide excellent and compassionate clinical care for my patients while seeking a better understanding of diseases I treat, particularly Celiac disease (CeD), eosinophilic esophagitis (EoE). My top priorities are patient care and translational research to make new discoveries and improve the care my patients. -
Michael Fischbach
Liu (Liao) Family Professor
Current Research and Scholarly InterestsThe microbiome carries out extraordinary feats of biology: it produces hundreds of molecules, many of which impact host physiology; modulates immune function potently and specifically; self-organizes biogeographically; and exhibits profound stability in the face of perturbations. Our lab studies the mechanisms of microbiome-host interactions. Our approach is based on two technologies we recently developed: a complex (119-member) defined gut community that serves as an analytically manageable but biologically relevant system for experimentation, and new genetic systems for common species from the microbiome. Using these systems, we investigate mechanisms at the community level and the strain level.
1) Community-level mechanisms. A typical gut microbiome consists of 200-250 bacterial species that span >6 orders of magnitude in relative abundance. As a system, these bacteria carry out extraordinary feats of metabolite consumption and production, elicit a variety of specific immune cell populations, self-organize geographically and metabolically, and exhibit profound resilience against a wide range of perturbations. Yet remarkably little is known about how the community functions as a system. We are exploring this by asking two broad questions: How do groups of organisms work together to influence immune function? What are the mechanisms that govern metabolism and ecology at the 100+ strain scale? Our goal is to learn rules that will enable us to design communities that solve specific therapeutic problems.
2) Strain-level mechanisms. Even though gut and skin colonists live in communities, individual strains can have an extraordinary impact on host biology. We focus on two broad (and partially overlapping) categories:
Immune modulation: Can we redirect colonist-specific T cells against an antigen of interest by expressing it on the surface of a bacterium? How do skin colonists induce high levels of Staphylococcus-specific antibodies in mice and humans?
Abundant microbiome-derived molecules: By constructing single-strain/single-gene knockouts in a complex defined community, we will ask: What are the effects of bacterially produced molecules on host metabolism and immunology? Can the molecular output of low-abundance organisms impact host physiology?
3) Cell and gene therapy. We have begun two new efforts in mammalian cell and gene therapies. First, we are developing methods that enable cell-type specific delivery of genome editing payloads in vivo. We are especially interested in delivery vehicles that are customizable and easy to manufacture. Second, we have begun a comprehensive genome mining effort with an emphasis on understudied or entirely novel enzyme systems with utility in mammalian genome editing.
